Target Price | $367.20 |
Price | $309.32 |
Potential |
18.71%
register free of charge
|
Number of Estimates | 22 |
22 Analysts have issued a price target Elevance Health 2026 .
The average Elevance Health target price is $367.20.
This is
18.71%
register free of charge
$584.15
88.85%
register free of charge
$299.97
3.02%
register free of charge
|
|
A rating was issued by 28 analysts: 18 Analysts recommend Elevance Health to buy, 10 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Elevance Health stock has an average upside potential 2026 of
18.71%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 176.81 | 198.61 |
3.19% | 12.33% | |
EBITDA Margin | 5.51% | 5.32% |
9.12% | 3.39% | |
Net Margin | 3.38% | 3.93% |
3.21% | 16.20% |
22 Analysts have issued a sales forecast Elevance Health 2025 . The average Elevance Health sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Elevance Health EBITDA forecast 2025. The average Elevance Health EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Elevance Health Analysts have issued a net profit forecast 2025. The average Elevance Health net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 25.68 | 34.75 |
1.82% | 35.32% | |
P/E | 8.91 | |
EV/Sales | 0.46 |
25 Analysts have issued a Elevance Health forecast for earnings per share. The average Elevance Health EPS is
This results in the following potential growth metrics and future valuations:
Elevance Health...
Analyst | Rating | Action | Date |
---|---|---|---|
Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 15 2025 |
Baird |
Locked
➜
Locked
|
Locked | Jul 25 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Jul 22 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Jul 22 2025 |
Argus Research |
Locked
➜
Locked
|
Locked | Jul 21 2025 |
Leerink Partners |
Locked
➜
Locked
|
Locked | Jul 18 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Jul 18 2025 |
Analyst Rating | Date |
---|---|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 15 2025 |
Locked
Baird:
Locked
➜
Locked
|
Jul 25 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Jul 22 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 22 2025 |
Locked
Argus Research:
Locked
➜
Locked
|
Jul 21 2025 |
Locked
Leerink Partners:
Locked
➜
Locked
|
Jul 18 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Jul 18 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.